-
Recent Posts
- Can Raptor Pharmaceutical Corp. (NASDAQ: RPTP) Turn FDA Approval into Big Payday Down the Road?
- Camtek Ltd. (NASDAQ: CAMT) Shares Climb After First Quarter Growth and Positive Outlook
- Is There Hope for Next Generation Corp. (OTCQB: NGMC) in Oil and Gas Industry?
- Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Spikes with Promise of Tasimelteon
- Is Enviro-Serv, Inc. (PINKSHEETS: EVSV) Any Closer to Generating Revenues?
Categories
OTC Equity Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
Tags
aapl advertising alternative energy amex apple basic materials biopharmaceutical biotechnology cancer capital goods cloud computing copper drilling energy energy stocks exploration facebook fda fda approval gas gold gold mining google healthcare stocks investors ipad iphone mining NASDAQ natural gas nyse oil oil and gas otcbb penny stock penny stocks petroleum pharmaceutical pinksheets Pink Sheets s silver sprint stocks tradingSite
OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.
Registration to our newsletter is FREE, Join today by entering your email below!
Tag Archives: nda
Has Aveo Pharmaceuticals, Inc. (NASDAQ: AVEO) Done Enough to Earn FDA Approval?
There are plenty of investors placing their bets on Aveo Pharmaceuticals, Inc. (NASDAQ: AVEO) as the cancer therapeutics company, doing business as Aveo Oncology, nears the date in which they will face the FDA’s Oncologic Drugs Advisory Committee (ODAC) for … Continue reading
Posted in Articles, NASDAQ
Tagged aveo, aveo pharmaceuticals, cancer therapeutics, fda, investors, nda, oncology, onx, rcc, tivozanib
Leave a comment
EnergySolutions, Inc. (NYSE: ES) Facing Uncertain Future in Nuclear Industry Despite Positive Earnings Report
It has been nearly two months since EnergySolutions, Inc. (NYSE: ES) went through a brutal three-day trading period in which their shares tumbled from a high of 3.64 to a low of 1.62 and while shares of the company, which … Continue reading
Posted in Articles, NYSE
Tagged energysolutions, es, investors, magnox, nda, nuclear industry, nuclear operations, nuclear waste
Leave a comment
Elite Pharmaceuticals, Inc. (OTCBB: ELTP) Continuing Development of Oral Controlled Release Product Formulations
It was a wild few days for Elite Pharmaceuticals, Inc. (OTCBB: ELTP) last week as shares of the specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations hit a six-month high of 0.1740 on Tuesday, fell … Continue reading
Posted in Uncategorized
Tagged elite pharmaceuticals, eltp, fda, investors, nda, oral dosage, penny stocks, specialty pharmaceutical company
Leave a comment
Future of Alexza Pharmaceuticals (NASDAQ: ALXA) Could be Determined Over the Next Six Months as NDA Ready for Submission to FDA Once More
With the resubmission of their New Drug Application to the FDA for AZ-004 now pushed back to August 8, 2011 shares in Alexza Pharmaceuticals (NASDAQ: ALXA) have dipped slightly, trading around the 1.47 – 1.53 range, sliding below their 50-day … Continue reading
Posted in Articles, NASDAQ, Penny Stocks
Tagged alexza pharmaceuticals, alxa, az-004, crl, drug delivery, fda, investors, loxapine, NASDAQ, nda, penny stocks, staccato
Leave a comment
Transcept Pharmaceuticals (NASDAQ: TSPT) Facing Difficult Task of Satisfying Lofty Demands of FDA for Approval of Intermezzo
Just what kind of shape Transcept Pharmaceuticals (NASDAQ: TSPT) is in remains unclear as the small biotech company looks for direction following a second rejection letter from the FDA concerning their insomnia drug Intermezzo. Despite the FDA’s acknowledgements that Intermezzo … Continue reading
Posted in Articles, NASDAQ, Penny Stocks
Tagged approval intermezzo, fda, insomnia, investors, NASDAQ, nda, penny stocks, sleep, transcept pharmaceuticals, tspt
Leave a comment


